WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory actions
Abrir esta carpeta y ver su contenidoDrug surveillance
Abrir esta carpeta y ver su contenidoNew developments
Abrir esta carpeta y ver su contenidoGeneral information
Cerrar esta carpetaMedication errors
Ver el documentoDecimal dosages: confusion: USA
Ver el documentoEltroxin (levothyroxine sodium): confusion in formulations: Ireland
Ver el documentoPegaspargase (Oncaspar): misleading graphics: USA
Ver el documentoRemeron (mirtazepine): strength confusion: USA
Ver el documentoTiagabine and tizanidine: name confusion and similar dosing and tablet strength: USA
Ver el documentoWarfarin (Coumadin): confusing instructions: USA
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Tiagabine and tizanidine: name confusion and similar dosing and tablet strength: USA

United States of America. Similar dosing and tablet strength for two drugs with look-alike generic names, tiagabine (Gabatril: Abbott) and tizanidine (Zanaflex: Athena Neurosciences) increases the potential for confusing these products.

Tiagabine, used to treat seizures, is available in 4 mg tablets with a dosage range from 4 mg daily to 8 mg four times daily. Tizanidine, used to treat muscle spasticity, is also available in 4 mg tablets with a dosage range of 4 mg to 8 mg every 6 to 8 hours.

Reference: ISMP Medication Safety Alert! Vol. 3, Issue 24, 1 December 1998.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013